PT Medikaloka Hermina Tbk.

heal

Overview

HEAL Overview

PT Medikaloka Hermina Tbk is an Indonesia-based company, which is engaged in offering general hospital services. The Company is focused on providing services for BPJS patients to support government program in Indonesia. The Company’s services include hospitals, specialties, and featured services. The Company’s hospitals include Hermina Arcamanik, Hermina Balikpapan, Hermina Banyumanik, Hermina Bekasi, Hermina Bitung, Hermina Bogor, Hermina Ciledug, Hermina Cilegon and Hermina Ciputat. In specialties service, the Company provides anatomical pathology, andrology, anesthesiology, cardiology, clinical microbiology, clinical pathology, dentistry, dermatology and venereology, dietetics, emergency medicine, forensic and medicolegal, internal medicine, medical acupuncture, neurology, and surgery. Its subsidiaries include PT Medikaloka Internusa (M Internusa), PT Medikaloka Sejahtera (M Sejahtera), PT Medikaloka Husada (M Husada), PT Medikaloka Daan Mogot and PT Medikaloka Pasteur (M Pasteur).

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: HEAL

Main
Market Cap.
IDR 19.03Trillion

~$1.20B USD

Industry
Healthcare Providers
Sub-Industry
Healthcare Providers
Sector
Healthcare

Valuation

HEAL Valuation Metrics

1,205

IDR

Closing Price on 2024-04-05

Price to Equity

39.48

P/E

At 39.48x P/E TTM, HEAL.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 23.8x).

Price to Book

5.15

P/B

At 5.15x P/B TTM, HEAL.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 1.8x).

Price to Sales

3.43

P/S

At 3.43x P/S TTM, HEAL.JK is trading in line with its peers in the Healthcare Equipment & Providers sector.

Valuing PT Medikaloka Hermina Tbk. based on its trailing twelve months (TTM) valuation metrics against its peers in the Healthcare Equipment & Providers sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Medikaloka Hermina Tbk. relative to other stocks in the Healthcare Equipment & Providers sector

Price/Cash Flow
16.30x
Price/Forward Earnings
23.05x
Enterprise Value/Revenue
3.67x
Enterprise Value/EBITDA
20.66x
PEG Ratio
0.49x

Analyst Ratings

40
60
80
0
100

85.0

Undervalued

Fairly Valued

Overvalued

Last closing: IDR1,2052024-04-05
IDR 278.28

Considerably Lower Intrinsic Value: Analyst's intrinsic value is of HEAL is IDR278, which is 76% lower than HEAL's last closing price of IDR1,205 (as of 2024-04-05).

Valuation Recap of HEAL stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 39.48x is above the ID market average of 8.22x and is trading at a premium to peers in the Healthcare Equipment & Providers sector (23.78x).
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 5.15x is above the peers average of 1.80x in the Healthcare Equipment & Providers sector. HEAL trades at a higher P/B ratio than >75% of its peers in the Healthcare Equipment & Providers sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 3.43x is similar to the peers average of 3.00x in the Healthcare Equipment & Providers sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of HEAL's valuation relative to its current sales and future earnings growth. HEAL trades at a Forward P/E ratio of 23.05x, which is considered richly valued by analysts.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. HEAL's P/CF ratio of 16.30x is considered a relatively high ratio by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. HEAL's EV/R ratio of 3.67x is considered a relatively high ratio The average EV/R ratio for the Healthcare Equipment & Providers sector is 2.98x.
Max 3
Medium
Considerably Lower Intrinsic Value: Analyst's intrinsic value is of HEAL is IDR 278.28, which is 76% lower than HEAL's last closing price of IDR 1,205.00.
Max 3

Peers

HEAL Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of HEAL stock
WeightNotesScore
High
At a market cap of IDR 19,030.69 billion, HEAL.JK ranks 6 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of 39.48, HEAL.JK ranks 3 out of 10 companies in the Healthcare sector for P/E value. The average PE is -17.68 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of 39.48, HEAL.JK is trading at a higher PE than that of its subsector peers in Healthcare Equipment & Providers (median of 23.78). false●●
Max 2
Medium
At a revenue of IDR 5.54 trillion, HEAL.JK ranks 5 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of IDR 0.48 trillion, HEAL.JK ranks 6 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of HEAL

Growth Forecasts

HEAL 2024 Revenue Growth
+31.4%
HEAL 2024 EPS Growth
+63.1%
Sector Revenue Growth
+23.7%
Healthcare Equipment & Providers
Indonesia Market Growth
+12.0%
IDX overall growth
Healthcare Equipment & Providers Sector Revenue Growth '24
+23.0%
Healthcare Sector Revenue Growth '24
+17.1%

Sector Benchmark

Healthcare Equipment & Providers companies in Indonesia are growing at a projected rate of 23.68% against the IDX average of +12.0%.

Healthcare Equipment & Providers sector overview

HEAL Earnings & Revenue Forecast

All values in IDR billion

Future growth prospect of HEAL
WeightNotesScore
High
HEAL's projected growth rate of 23.68% is above the ID market average of 11.98%.●●●
Max 3
High
The Healthcare Equipment & Providers sub-sector is projected to grow revenue by 22.97% in 2024. This number is higher than the previous year 2023's growth rate of 9.96%. This bodes well for HEAL's revenue growth prospects in the next 2 years. ●●●
Max 3
Medium
The Healthcare Equipment & Providers sub-sector is projected to increase earnings by 29.75% in 2024. This number is higher than the previous year 2023's EPS growth of 9.77%. This bodes well for HEAL's earnings growth prospects in the next 2 years. ●●●
Max 3
Medium
HEAL and its peers in the Healthcare Equipment & Providers sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for HEAL's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Hasmoro15.2 years
Binsar Parasian Simorangkir
Director
Yulisar Khiat
Director
Aristo Sungkono Setiawidjaja
Director
NamePositionShares%
Binsar Parasian SimorangkirDirector867,879,5005.8
Yulisar KhiatDirector1,752,656,00011.71
Expressed in millions IDR, unless otherwise stated

Ownership

HEAL Ownership

Others
47.56%
Insiders
47.06%
Institutions
5.38%
NameNumber of SharesOwnership (%)Value
Public (Scripless)8,763,844,59558.5510,560.43B
Yulisar Khiat1,752,656,00011.712,111.95B
Pt Astra International Tbk1,110,824,0007.421,338.54B
Binsar Parasian Simorangkir867,879,5005.81,045.79B
Lydia Immanuel855,082,0005.711,030.37B
Soerpardiman755,556,0005.05910.44B
Treasury Stock475,920,0003.18573.48B
Public (Scrip)385,837,0002.58464.93B

Largest Institutional Buy

State Street Global Advisors
Bought 31-12-2023
+7,735,614 shares
J O Hambro Capital Management Limited
Bought 31-12-2023
+3,793,300 shares
Morgan Stanley Investment Management Ltd
Bought 31-12-2023
+1,343,200 shares

Largest Institutional Sell

Vanguard Group Inc
Sold 31-12-2023
-148,470,702 shares
Vanguard Equity Investment Group
Sold 31-12-2023
-29,040,364 shares
BlackRock Advisors (UK) Limited
Sold 31-12-2023
-9,260,900 shares

Institutional Transactions

Tracking institutional transactions buying / selling of HEAL stock